Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) have been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $22.63.
Several brokerages have issued reports on ATEC. Needham & Company LLC boosted their price target on Alphatec from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, December 19th. Roth Mkm assumed coverage on Alphatec in a research report on Friday, October 20th. They set a “buy” rating and a $22.00 target price on the stock. Wells Fargo & Company assumed coverage on Alphatec in a research report on Friday. They set an “overweight” rating and a $26.00 target price on the stock. Morgan Stanley lowered their target price on Alphatec from $23.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 14th. Finally, Stifel Nicolaus lowered their target price on Alphatec from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th.
Alphatec Stock Performance
Insider Transactions at Alphatec
In other news, EVP David Sponsel sold 2,500 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $15.00, for a total transaction of $37,500.00. Following the completion of the transaction, the executive vice president now owns 555,280 shares in the company, valued at approximately $8,329,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 29.12% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in ATEC. BluePath Capital Management LLC purchased a new stake in shares of Alphatec in the 3rd quarter valued at about $29,000. Comerica Bank purchased a new stake in shares of Alphatec in the 3rd quarter valued at about $36,000. Macquarie Group Ltd. purchased a new stake in shares of Alphatec in the 1st quarter valued at about $40,000. Point72 Hong Kong Ltd purchased a new stake in shares of Alphatec in the 2nd quarter valued at about $46,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Alphatec in the 2nd quarter valued at about $49,000. Institutional investors own 67.19% of the company’s stock.
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization.
- Five stocks we like better than Alphatec
- How to Invest in Canada for Beginners
- 3 attractive stocks that insiders are buying
- What does consumer price index measure?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Blockchain Stocks Step by Step
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.